ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 782

Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World

Johan Askling1, Niklas Berglind2, Stefan Franzén2, Thomas Frisell3, Christopher Garwood4, Jeffrey D. Greenberg5, Meilien Ho6, Marie Holmqvist1, Laura Horne7, Kathy Lampl8, Kaleb Michaud9, Fredrik Nyberg10, Dimitrios A. Pappas11, George Reed12, Eiichi Tanaka13, Trung Tran14, Suzanne Verstappen4, Hisashi Yamanaka15 and Deborah Symmons4, 1Karolinska Institutet, Stockholm, Sweden, 2AstraZeneca R&D Mölndal, Mölndal, Sweden, 3Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 6AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 7AstraZeneca, Wilmington, DE, 8AstraZeneca R&D Wilmington, Wilmington, DE, 9University of Nebraska Medical Center and National Data Bank, Omaha, NE, 10AstraZeneca R&D, Mölndal, Sweden, 11Columbia University, New York, NY, 12University of Massachusetts Medical School, Worcester, MA, 13Tokyo Women's Medical University, Tokyo, Japan, 14MedImmune LLC, Gaithersburg, MD, 15Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Co-morbidities, Epidemiologic methods, Malignancy, registries and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer rates in RA populations vary across cohorts and across patient subsets defined by disease activity or treatment is less known. Available data are often difficult to compare, since background malignancy rates may vary across the world, and due to methodological differences and population differences between studied RA cohorts. We investigated malignancy rates in 5 international RA registries from 4 continents, employing a standard set of analyses and standardizing rates to a common population.

Methods: Participating RA registries were CORRONA (USA), SRR (Sweden), NOAR (UK), CORRONA International (East Europe, Latin America, India) and IORRA (Japan). Within each registry, we analyzed a primary cohort of all RA patients from January 2000 to last available data of each register (2010–2013), and several subcohorts as defined by disease activity, treatment status, calendar time, duration of follow-up and prior comorbidity for sensitivity analyses. Malignancy rates with 95% confidence intervals were estimated, and were standardized for age, sex and, in 1 sensitivity analysis, also for HAQ, using the distributions from a typical RA trial program population.

Results: There was remarkable consistency in crude malignancy rates across registries (Table). Sex and age standardization reduced heterogeneity further, with standardized rates of malignancy excluding nonmelanoma skin cancer (NMSC) varying from 0.56 to 0.87 per 100 person-years (Table). Within each registry, rates were generally also consistent across the sensitivity analyses, which also differed little from the main analyses based on the full cohort (data not shown).

Conclusion: A consistent methodology and analysis with standardization of rates facilitated comparison across registries and demonstrated that in real world RA populations from different countries and with variations in RA management and comorbidity, rates of overall malignancy excluding NMSC and of lymphoma were surprisingly consistent across and within the cohorts.

 

 


Disclosure:

J. Askling,

AstraZeneca,

2,

AstraZeneca,

5;

N. Berglind,

AstraZeneca, Bristol-Myers Squibb,

1,

AstraZeneca,

3;

S. Franzén,

AstraZeneca,

1,

AstraZeneca,

3;

T. Frisell,
None;

C. Garwood,
None;

J. D. Greenberg,

AstraZeneca, CORRONA, Pfizer,

5,

Corrona,

1;

M. Ho,

AstraZeneca,

3;

M. Holmqvist,
None;

L. Horne,

AstraZeneca,

1,

AstraZeneca,

3;

K. Lampl,

AstraZeneca,

1,

AstraZeneca,

3;

K. Michaud,

University of Nebraska Medical Center and the National Data Bank for Rheumatic Diseases,

3;

F. Nyberg,

AstraZeneca,

3,

AstraZeneca,

1;

D. A. Pappas,

Corrona,

3,

Novartis Pharmaceutical Corporation,

5,

Adjunct assistant professor at Columbia University,

6;

G. Reed,

Corrona,

3;

E. Tanaka,
None;

T. Tran,

Medimmune LLC,

3;

S. Verstappen,
None;

H. Yamanaka,

AstraZeneca, Abbott, AbbVie, Chugai, Takeda, Pfizer, Daiichi Sankyo, Mitsubishi Tanabe, Teijin, Nippon Kayaku, Taishotoyama, Bristol-Myers Squibb, Astellas, Eisai, MSD, Santen, GlaxoSmithKline, Asahikasei, Janssen,

2,

AstraZeneca, Abbott, AbbVie, Chugai, Takeda, Pfizer, Daiichi Sankyo, Mitsubishi Tanabe, Teijin, Nippon Kayaku, Bristol-Myers Squibb, Astellas, Eisai,

5,

Abbott, AbbVie, Chugai, Takeda, Pfizer, Mitsubishi Tanabe, Teijin, Bristol-Myers Squibb, Astellas, Eisai,

8;

D. Symmons,

AstraZeneca,

2,

AstraZeneca,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rates-of-malignancies-in-patients-from-5-rheumatoid-arthritis-registries-across-the-world/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology